EPIM
ARQT icon

Evelyn Partners Investment Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Evelyn Partners Investment Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-270
Closed -$7.84K – 414
2025
Q4 		$7.84K Hold
270
– – ﹤0.01% 369
2025
Q3 		$5.09K Hold
270
– – ﹤0.01% 373
2025
Q2 		$3.79K Hold
270
– – ﹤0.01% 379
2025
Q1 		$4.22K Hold
270
– – ﹤0.01% 377
2024
Q4 		$3.76K Buy
+270
New +$2.96K ﹤0.01% 385

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Evelyn Partners Investment Management's ARQT Position: Q1 2026 in Review

Evelyn Partners Investment Management sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 270 shares — an estimated $7.84K sold.

Evelyn Partners Investment Management first reported a position in ARQT in Q4 2024 and held it in 5 quarters. The position peaked at $7.84K in Q4 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Evelyn Partners Investment Management reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Evelyn Partners Investment Management sold 270 Arcutis Biotherapeutics shares in Q1 2026, an estimated $7.84K.
  • Evelyn Partners Investment Management first reported a position in Arcutis Biotherapeutics in Q4 2024 and held it in 5 quarters.
  • Evelyn Partners Investment Management's Arcutis Biotherapeutics position peaked at $7.84K in Q4 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Evelyn Partners Investment Management's 13F filing for Q1 2026, filed 15 May 2026.